{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:42:44Z","timestamp":1760168564378,"version":"build-2065373602"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["15821"],"award-info":[{"award-number":["15821"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Caveolin-1 (Cav-1) plays a key role in various neoplastic diseases and is upregulated in different cancers, including pancreatic ductal adenocarcinoma (PDAC). Furthermore, Cav-1 is critical for the uptake of albumin as well as nab-paclitaxel in PDAC cells. Here, we investigated the prognostic impact of Cav-1 expression in a cohort of 39 metastatic PDAC patients treated with different first-line chemotherapy regimens. We also assessed the predictive value of Cav-1 in patients treated with gemcitabine and nab-paclitaxel. Cav-1 expression was evaluated by immunohistochemistry staining in neoplastic and stromal cells, using metastatic sites or primary tumor tissue specimens. Higher levels of Cav-1 expression were associated with significantly worse overall survival (OS) and progression-free survival (PFS). No differences in OS were found between patients treated with gemcitabine + nab-paclitaxel vs. other chemotherapy options. Multivariate analysis for OS and PFS confirmed the independent prognostic role of Cav-1 expression. Our study evidenced a negative prognostic role of Cav-1 in patients affected by metastatic\/locally advanced unresectable PDAC. Moreover, Cav-1 expression seems not to predict different response rates to different types of first-line treatment. Future prospective trials will be necessary to confirm the prognostic role of Cav-1 and explore Cav-1 specific inhibitors as a therapeutic option for advanced PDAC patients.<\/jats:p>","DOI":"10.3390\/curroncol28050303","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T21:28:45Z","timestamp":1631136525000},"page":"3525-3536","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients"],"prefix":"10.3390","volume":"28","author":[{"given":"Alessandro","family":"Bittoni","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Giampieri","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Pecci","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-2104","authenticated-orcid":false,"given":"Giada","family":"Pinterpe","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Mandolesi","sequence":"additional","affiliation":[{"name":"Department of Pathological Anatomy and Histopathology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-487X","authenticated-orcid":false,"given":"Michela","family":"Del Prete","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale A. Murri, 63900 Fermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Zizzi","sequence":"additional","affiliation":[{"name":"Department of Pathological Anatomy and Histopathology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Crocetti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Liguori","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Mentrasti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-4758","authenticated-orcid":false,"given":"Luca","family":"Cantini","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pellei","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"},{"name":"Medical Oncology Unit, Ospedale Madonna del Soccorso, 63074 San Benedetto del Tronto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Bisonni","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale A. Murri, 63900 Fermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Scarpelli","sequence":"additional","affiliation":[{"name":"Department of Pathological Anatomy and Histopathology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/07853890410018899","article-title":"The Caveolin genes: From cell biology to medicine","volume":"36","author":"Williams","year":"2004","journal-title":"Ann. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/ATVBAHA.120.314291","article-title":"Cav-1 (Caveolin-1) Deficiency Increases Autophagy in the Endothelium and Attenuates Vascular Inflammation and Atherosclerosis","volume":"40","author":"Zhang","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/sj.bjc.6600619","article-title":"Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma","volume":"87","author":"Suzuoki","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1476-4598-4-21","article-title":"Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1","volume":"4","author":"Lin","year":"2005","journal-title":"Mol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0002-9440(10)64442-2","article-title":"Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation","volume":"161","author":"Ho","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1038\/sj.onc.1210498","article-title":"Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1","volume":"26","author":"Cordes","year":"2007","journal-title":"Oncogene"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10867","DOI":"10.1038\/srep10867","article-title":"Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer","volume":"5","author":"Chatterjee","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.radonc.2009.07.004","article-title":"Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells","volume":"92","author":"Hehlgans","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_13","first-page":"537","article-title":"Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model","volume":"54","author":"Kamposioras","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1158\/0008-5472.CAN-17-0604","article-title":"Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy","volume":"77","author":"Chatterjee","year":"2017","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"22","author":"Ilic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1756284820948773","DOI":"10.1177\/1756284820948773","article-title":"Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers","volume":"13","author":"Eso","year":"2020","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"35087","DOI":"10.18632\/oncotarget.5197","article-title":"Italian Group for the Study of Digestive Tract Cancer (GISCAD). The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib","volume":"6","author":"Faloppi","year":"2015","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3389\/fonc.2019.00874","article-title":"Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival","volume":"9","author":"Amantini","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Buscail, E., Alix-Panabi\u00e8res, C., Quincy, P., Cauvin, T., Chauvet, A., Degrandi, O., Caumont, C., Verdon, S., Lamrissi, I., and Moranvillier, I. (2019). High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery. Cancers, 11.","DOI":"10.3390\/cancers11111656"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Giampieri, R., Piva, F., Occhipinti, G., Bittoni, A., Righetti, A., Pagliaretta, S., Murrone, A., Bianchi, F., Amantini, C., and Giulietti, M. (2019). Clinical impact of different exosomes\u2019 protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215990"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4614-1222-9_3","article-title":"Caveolin-1: Role in cell signaling","volume":"729","author":"Boscher","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4143\/crt.2015.227","article-title":"Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms","volume":"48","author":"Kang","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Lv, F., Chen, S., Wang, Z., Zhang, J., Zhang, S., Cao, J., Wang, L., Cao, E., and Wang, B. (2018). Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4936-y"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.21037\/cco.2019.01.08","article-title":"Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?","volume":"8","author":"Ricci","year":"2019","journal-title":"Chin. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14656566.2018.1546290","article-title":"Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: An evaluation of the clinical evidence","volume":"20","author":"Ashai","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Campos, A., Burgos-Ravanal, R., Gonz\u00e1lez, M.F., Huilcaman, R., Lobos Gonz\u00e1lez, L., and Quest, A.F.G. (2019). Cell intrinsic and extrinsic mechanisms of caveolin-1- enhanced metastasis. Biomolecules, 9.","DOI":"10.3390\/biom9080314"},{"key":"ref_29","first-page":"5719","article-title":"Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker","volume":"59","author":"Yang","year":"1999","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"562774","DOI":"10.3389\/fonc.2020.562774","article-title":"Association of Caveolin-1 Expression with Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"10","author":"Chen","year":"2021","journal-title":"Front Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/pcmr.12085","article-title":"E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells","volume":"26","author":"Aguilar","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/CMR.0000000000000046","article-title":"Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models","volume":"24","author":"Fernandez","year":"2014","journal-title":"Melanoma Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3892\/or.2011.1605","article-title":"Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas","volume":"27","author":"Zhan","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12253-017-0212-8","article-title":"Expression of Stromal Caveolin- 1 May Be a Predictor for Aggressive Behaviour of Breast Cancer","volume":"24","author":"Eliyatkin","year":"2018","journal-title":"Pathol. Oncol. Res."},{"key":"ref_35","first-page":"2977","article-title":"Inhibition of Caveolin-1 expression by Incandronate in PC-3 prostate cells","volume":"26","author":"Iguchi","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_36","first-page":"1291","article-title":"Caveolin-1 as a novel target of therapeutic activity of Fenretinide in osteosarcoma and glioblastoma in vitro","volume":"66","author":"Baiocchi","year":"2006","journal-title":"Proc. Amer. Assoc. Cancer Res."},{"key":"ref_37","first-page":"1037","article-title":"Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications of colon cancer prevention","volume":"35","author":"Guruswamy","year":"2009","journal-title":"Int. J. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/5\/303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:59:09Z","timestamp":1760165949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/5\/303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["curroncol28050303"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28050303","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}